TransCode Therapeutics announced that Thomas A. Fitzgerald resigned as Chief Financial Officer and director effective September 9, 2026, due to no disagreement with the company. His resignation triggers a Separation Agreement providing up to $1,250,000 in severance, contingent on funding thresholds of $5 million or $10 million within one year. All outstanding equity awards vested immediately, and he received a new option for 185,000 shares with performance-based acceleration. John Tattory was appointed Interim CFO effective the same date. TransCode Therapeutics operates in the biotechnology industry, focusing on developing RNA-based therapeutics.

TransCode Therapeutics filed a Second Amended and Restated Certificate of Designation for its Series A and Series B Non-Voting Convertible Preferred Stock on August 3, 2026. This amendment removed the requirement for 60 days' notice to change or waive the beneficial ownership limitation previously set in the October 2025 designation. No additional securities were issued or sold in connection with this filing. TransCode Therapeutics operates in the biotechnology industry, focusing on developing therapies for rare diseases.

At its 2026 Annual Meeting on July 20, 2026, TransCode Therapeutics, Inc. stockholders approved several material items. These include the issuance of common stock upon the conversion of Series A, B, and C Non-Voting Convertible Preferred Stock, and the issuance of common stock under a Standby Equity Purchase Agreement and convertible promissory notes with YA II PN, Ltd. Additionally, stockholders approved increasing the 2021 Stock Option and Incentive Plan by 1,734,262 shares. The company also elected six directors and ratified WithumSmith+Brown, PC as its independent auditor. TransCode Therapeutics is a biotechnology company that develops therapeutic candidates.

TransCode Therapeutics, Inc. filed an Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock on July 16, 2026. Following approval from the Board of Directors and a majority of Series C Preferred Stock holders, the amendment increased the beneficial ownership limitation for Series C holders from 4.99% to 9.99%. The filing also included non-substantive corrections to scrivener's errors, with no additional securities issued or sold. TransCode Therapeutics, Inc. is a biotechnology company focused on RNA therapeutics.

TransCode Therapeutics, Inc. adjourned its 2026 Annual Meeting of Stockholders to July 20, 2026, to allow Nasdaq to complete its review of the company's initial listing application. Preliminary voting reports indicate that all agenda proposals, including the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock, are receiving necessary support. TransCode Therapeutics, Inc. operates in the biotechnology industry and develops therapeutic solutions using advanced genetic technologies.